Carlos A Dujovne

Summary

Affiliation: Radiant Research
Country: USA

Publications

  1. ncbi Randomized comparison of the efficacy and safety of cerivastatin and pravastatin in 1,030 hypercholesterolemic patients. The Cerivastatin Study Group
    C A Dujovne
    Kansas Foundation for Clinical Pharmacology, Radiant Research, Kansas City, Overland Park 66215, USA
    Mayo Clin Proc 75:1124-32. 2000
  2. ncbi Effect of atorvastatin on hemorheologic-hemostatic parameters and serum fibrinogen levels in hyperlipidemic patients
    C A Dujovne
    Lipid, Arteriosclerosis and Metabolic Clinic, University of Kansas Medical Center, Kansas City, USA
    Am J Cardiol 85:350-3. 2000
  3. ncbi Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia
    Carlos A Dujovne
    Kansas Foundation for Clinical Pharmacology, Radiant Research Kansas City, 12200 W 106th Street, Suite 330, Overland Park, KS 66215, USA
    Am J Cardiol 90:1092-7. 2002
  4. ncbi Effectiveness and tolerability of a new lipid-altering agent, gemcabene, in patients with low levels of high-density lipoprotein cholesterol
    Harold E Bays
    Louisville Metabolic and Atherosclerosis Research Center, Louisville, Kentucky 40213, USA
    Am J Cardiol 92:538-43. 2003
  5. ncbi Side effects of statins: hepatitis versus "transaminitis"-myositis versus "CPKitis"
    Carlos A Dujovne
    Am J Cardiol 89:1411-3. 2002
  6. ncbi Effects of simvastatin, an HMG-CoA reductase inhibitor, in patients with hypertriglyceridemia
    Jonathan Isaacsohn
    Metabolic and Atherosclerosis Research Center, Cincinnati, Ohio, USA
    Clin Cardiol 26:18-24. 2003
  7. ncbi Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE])
    Harold E Bays
    Louisville Metabolic and Atherosclerosis Research Center, Louisville, Kentucky 40213, USA
    Am J Cardiol 91:667-72. 2003
  8. ncbi Differential effects of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I are consistent across hypercholesterolemic patient subgroups
    Michael H Davidson
    Chicago Center for Clinical Research, Chicago, Illinois 60610, USA
    Clin Cardiol 26:509-14. 2003

Detail Information

Publications8

  1. ncbi Randomized comparison of the efficacy and safety of cerivastatin and pravastatin in 1,030 hypercholesterolemic patients. The Cerivastatin Study Group
    C A Dujovne
    Kansas Foundation for Clinical Pharmacology, Radiant Research, Kansas City, Overland Park 66215, USA
    Mayo Clin Proc 75:1124-32. 2000
    ..To determine the relative efficacy and safety of cerivastatin and pravastatin in patients with type II hypercholesterolemia...
  2. ncbi Effect of atorvastatin on hemorheologic-hemostatic parameters and serum fibrinogen levels in hyperlipidemic patients
    C A Dujovne
    Lipid, Arteriosclerosis and Metabolic Clinic, University of Kansas Medical Center, Kansas City, USA
    Am J Cardiol 85:350-3. 2000
    ....
  3. ncbi Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia
    Carlos A Dujovne
    Kansas Foundation for Clinical Pharmacology, Radiant Research Kansas City, 12200 W 106th Street, Suite 330, Overland Park, KS 66215, USA
    Am J Cardiol 90:1092-7. 2002
    ..Ezetimibe 10 mg/day is well tolerated, reduces LDL cholesterol approximately 17%, and improves other key lipid parameters...
  4. ncbi Effectiveness and tolerability of a new lipid-altering agent, gemcabene, in patients with low levels of high-density lipoprotein cholesterol
    Harold E Bays
    Louisville Metabolic and Atherosclerosis Research Center, Louisville, Kentucky 40213, USA
    Am J Cardiol 92:538-43. 2003
    ..At the higher doses, gemcabene significantly reduced LDL cholesterol levels in all patients with low HDL cholesterol...
  5. ncbi Side effects of statins: hepatitis versus "transaminitis"-myositis versus "CPKitis"
    Carlos A Dujovne
    Am J Cardiol 89:1411-3. 2002
  6. ncbi Effects of simvastatin, an HMG-CoA reductase inhibitor, in patients with hypertriglyceridemia
    Jonathan Isaacsohn
    Metabolic and Atherosclerosis Research Center, Cincinnati, Ohio, USA
    Clin Cardiol 26:18-24. 2003
    ..05 - < 0.001). CONCLUSION: The results of this study demonstrate the beneficial effects of simvastatin in patients with hypertriglyceridemia...
  7. ncbi Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE])
    Harold E Bays
    Louisville Metabolic and Atherosclerosis Research Center, Louisville, Kentucky 40213, USA
    Am J Cardiol 91:667-72. 2003
    ....
  8. ncbi Differential effects of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I are consistent across hypercholesterolemic patient subgroups
    Michael H Davidson
    Chicago Center for Clinical Research, Chicago, Illinois 60610, USA
    Clin Cardiol 26:509-14. 2003
    ..In addition to lowering plasma levels of low-density lipoprotein cholesterol (LDL-C), statins also raise high-density lipoprotein cholesterol (HDL-C)...